Hematologic Oncology

Rafael F. Duarte, MD, PhD, FRCP, presents 2 real-world clinical cases in which the investigational monoclonal antibody narsoplimab demonstrated clinical benefit in patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Eleni Gavriilaki, MD, PhD, discusses the rationale for the lectin pathway as a therapeutic target in hematopoietic stem cell transplantation–associated thrombotic microangiopathy.

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.

Brian T. Hill, MD, PhD, sheds light on XPO1 as a target in diffuse large B-cell lymphoma, the emergence of selinexor in the treatment landscape, and exciting agents in the pipeline.

Sandy Wong, MD, discusses the ANDROMEDA trial, the need for further investigation of venetoclax, and research with anti-amyloid fibril drugs in light chain amyloidosis.

Meletios A. Dimopoulos, MD, discusses the goal of the phase 3 ASPEN trial in Waldenström macroglobulinemia.

Naval G. Daver, MD, discusses the tolerability of magrolimab plus azacitidine in patients with acute myeloid leukemia and myelodysplastic syndrome.

Srdan Verstovsek, MD, PhD, discusses the phase 2 MANIFEST study, which examined CPI-0610 as an “add-on” to ruxolitinib in patients with myelofibrosis.

Lori A. Leslie discusses several key studies evaluating emerging approaches in the relapsed/refractory follicular lymphoma paradigm.

Pashna N. Munshi, MD, discusses the CAR T-cell therapies that have emerged in the lymphoma space and highlights the next steps for research with these products.

Investigators are evaluating the efficacy of enzastaurin, a PCKß inhibitor, in combination with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with high-risk DGM1–positive diffuse large B-cell lymphoma.

The novel investigational STAMP inhibitor asciminib significantly improved the major molecular response rate compared with bosutinib at 24 weeks in adult patients with Philadelphia chromosome–positive, chronic-phase chronic myeloid leukemia who received prior treatment with 2 or more TKIs.

Enasidenib in combination with best supportive care failed to significantly improve overall survival in patients with relapsed/refractory acute myeloid leukemia whose tumors harbor an IDH2 mutation.

Tafasitamab has been added to the Clinical Practice Guidelines in Oncology by the National Comprehensive Cancer Network for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant.

The novel phospholipid-drug conjugate CLR 131 induced a 100% overall response rate in patients with relapsed/refractory lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.

Ajai Chari, MD, discusses next steps with belantamab mafodotin-blmf and combination studies in multiple myeloma.

Mikkael A. Sekeres, MD, discusses staging patients with myelodysplastic syndromes.

Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.

John M. Pagel, MD, PhD, discusses challenges with autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma.

Grzegorz S. Nowakowski, MD, discusses the rationale for reevaluating the PCKß inhibitor enzastaurin in diffuse large B-cell lymphoma.

Sandy Wong, MD, discusses the potential role of venetoclax in relapsed/refractory light chain amyloidosis.

The approval of tazemetostat has expanded the portfolio of treatment options for relapsed/refractory follicular lymphoma, a disease for which new agents are needed because patients do not uniformly derive benefit from available therapies.

Jennifer Woyach, MD, discusses the role of small molecule inhibitors in chronic lymphocytic leukemia.

Kami J. Maddocks, MD, discusses the clinical implications of the approval of tafasitamab and lenalidomide in relapsed/refractory DLBCL, as well as remaining challenges that future research efforts should address.

John M. Pagel, MD, PhD, discusses the importance of screening patients for double-hit and triple-hit diffuse large B-cell lymphoma.

The FDA’s Oncologic Drugs Advisory Committee voted 8 to 2 in favor of approving remestemcel-L for the treatment of children with steroid-refractory acute graft-versus-host disease.

The FDA has granted a priority review designation to a new drug application for umbralisib for the treatment of patients with previously treated marginal zone lymphoma who have received at least 1 prior anti-CD20–based treatment.

Grzegorz S. Nowakowski, MD, discusses the potential clinical implications of the ongoing, randomized phase 3 ENGINE study in patients with high-risk Denovo Genomic Marker 1–positive diffuse large B-cell lymphoma.

Jennifer Woyach, MD, discusses ​the role of chemoimmunotherapy in chronic lymphocytic leukemia.

John M. Pagel, MD, PhD, discusses current treatment approaches in frontline and relapsed/refractory DLBCL and provides insight on some of the agents that are generating excitement in the relapsed/refractory setting.